Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di fase 2 sull'efficacia e sulla sicurezza di GAL-101, soluzione oftalmica al 2% nell'atrofia geografica non foveale secondaria all'AMD non neovascolare (eDREAM)

9 novembre 2026 aggiornato da: Galimedix Therapeutics Inc

Uno studio di fase 2, in doppio cieco, randomizzato, multicentrico, a gruppi paralleli, controllato con placebo per indagare l'efficacia e la sicurezza di GAL-101, soluzione oftalmica al 2%, in pazienti con atrofia geografica non foveale secondaria ad età non neovascolare. Degenerazione maculare correlata: studio EDREAM

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).

During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.

The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Galimedix Inc. c/o Imperial CRS, MD
  • Numero di telefono: +1 (301) 9179191
  • Email: info@galimedix.com

Backup dei contatti dello studio

Luoghi di studio

      • Yerevan, Armenia, 0048
        • Reclutamento
        • Ophthalmological Center After S.V. Malayan
        • Contatto:
        • Investigatore principale:
          • Lilit Voskanyan, MD, PhD
      • Bordeaux, Francia, 33000
        • Reclutamento
        • Centre Rétine Gallien
        • Contatto:
        • Investigatore principale:
          • Eric Fourmaux, MD
      • Lyon, Francia, 69317
        • Reclutamento
        • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
        • Contatto:
        • Investigatore principale:
          • Laurent KODJIKIAN, MD
      • Marseille, Francia, 13008
        • Reclutamento
        • Centre Monticelli Paradis d'Ophtalmologie
        • Contatto:
        • Investigatore principale:
          • François Devin, MD
      • Paris, Francia, 75006
        • Reclutamento
        • Centre Ophtalmologique Odéon
        • Contatto:
        • Contatto:
          • Favard, MD
        • Investigatore principale:
          • Catherine Favard, MD
      • Tours, Francia, 37540
        • Reclutamento
        • Centre médico-chirurgical de Touraine
        • Contatto:
        • Investigatore principale:
          • Sam Razavi, MD
      • Tbilisi, Georgia, 0162
        • Reclutamento
        • Akhali Mzera Limited
        • Contatto:
          • Revaz Bezarashvili
          • Numero di telefono: (+995) 555 55 54 82
          • Email: rezieye@gmail.com
        • Investigatore principale:
          • Shalva Skhirtladze, MD
      • Tbilisi, Georgia, 0186
        • Reclutamento
        • Caucasus Medical Centre LLC
        • Contatto:
        • Investigatore principale:
          • Mikheil Omiadze, MD, PhD
      • Bonn, Germania, 53127
        • Reclutamento
        • Universitäts-Augenklinik Bonn
        • Investigatore principale:
          • Kristina Pfau, MD
        • Contatto:
      • Freiburg im Breisgau, Germania, 79106
        • Reclutamento
        • Universitätsklinikum Freiburg Klinik für Augenheilkunde
        • Investigatore principale:
          • Hansjuergen Agostini, MD
        • Contatto:
      • Hanover, Germania, 30625
      • Neubrandenburg, Germania, 17036
        • Reclutamento
        • Dietrich Bonhoeffer Klinikum
        • Contatto:
        • Investigatore principale:
          • Christian Brinkmann, MD
      • Tübingen, Germania, 72076
        • Reclutamento
        • Universitätsklinikum Tübingen, Department für Augenheilkunde.
        • Contatto:
        • Investigatore principale:
          • Felix Reichel, MD
      • Ulm, Germania, 89075
        • Non ancora reclutamento
        • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
        • Contatto:
        • Investigatore principale:
          • Armin Wolf, MD
      • Kildare, Irlanda, W91 W535
        • Reclutamento
        • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
        • Investigatore principale:
          • Eugene Ng, MD
        • Contatto:
      • Waterford, Irlanda, X91 DH9W
        • Reclutamento
        • Institute of Eye Surgery (IOES Waterford)
        • Investigatore principale:
          • Eugene Ng, MD
        • Contatto:
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Hadassah Medical Center
        • Contatto:
        • Investigatore principale:
          • Tareq Jaouni, MD
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Tel Aviv Medical Center
        • Contatto:
        • Investigatore principale:
          • Omer Trivizki, MD
    • Milano
      • Milan, Milano, Italia, 20123
        • Reclutamento
        • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
        • Contatto:
        • Investigatore principale:
          • Stela Vujosevic, MD
      • Milan, Milano, Italia, 20132
        • Reclutamento
        • Unità di Oculistica, IRCCS Ospedale San Raffaele
        • Contatto:
        • Investigatore principale:
          • Francesco Bandello, MD
    • Roma
      • Roma, Roma, Italia, 00184
        • Reclutamento
        • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
        • Contatto:
        • Investigatore principale:
          • Mariacristina Parravanno, MD
    • California
      • Beverly Hills, California, Stati Uniti, 90211
        • Reclutamento
        • Retina-Vitreous Associates Medical Group
        • Investigatore principale:
          • David Boyer, MD
        • Contatto:
      • Walnut Creek, California, Stati Uniti, 94598
        • Reclutamento
        • Bay Area Retina Associates
        • Investigatore principale:
          • Roger Goldberg, MD
        • Contatto:
    • Maryland
      • Hagerstown, Maryland, Stati Uniti, 21740
        • Sospeso
        • Cumberland Valley Retina Consultants

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

55 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • ≥55 years of age

  • Willing and able to provide written informed consent

  • Willing and able to comply with the study schedule and study assessments

  • Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

  • BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

  • Refractive error between +3 and -6 diopters spherical equivalent in the study eye

  • Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

  • Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

    1. Well-delineated cumulative GA area between 1.25 and 12.0 mm2
    2. If GA is multifocal, at least 1 lesion ≥1.25 mm2
    3. GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
    4. GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
    5. GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
    6. GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
    7. Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria:

  1. Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

  2. History of laser therapy in the macular region, regardless of indication

  3. History of herpes zoster

  4. Ophthalmic disease or condition that requires or is likely to require surgery during the study period

  5. GA with cumulative area <1.25 mm2

  6. Any GA lesion within 100 µm radius from the center point of the fovea

  7. Axial length >26 mm

  8. Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

  9. Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

  10. Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

  11. Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

  12. Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period

    Non-study Eye:

  13. BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)

    Either Eye:

  14. History of uveitis

  15. GA secondary to any condition other than non-neovascular AMD

  16. History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

  17. Underwent investigational treatment for AMD within 6 months before Visit 1a

    General Exclusion Criteria:

  18. History of therapeutic radiation to the cranium

  19. Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

  20. History of malignant disease

  21. Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

  22. Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

  23. Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period

  24. Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

  25. Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

  26. Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

  27. Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: GAL-101 ophthalmic solution

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Comparatore placebo: Placebo

Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Lasso di tempo: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).

From baseline to last on-treatment visit (48 up to 96 weeks)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Lasso di tempo: From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)

From baseline to last on-treatment visit (48 up to 96 weeks)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 gennaio 2025

Completamento primario (Stimato)

30 marzo 2028

Completamento dello studio (Stimato)

30 maggio 2028

Date di iscrizione allo studio

Primo inviato

23 ottobre 2024

Primo inviato che soddisfa i criteri di controllo qualità

24 ottobre 2024

Primo Inserito (Effettivo)

26 ottobre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • GAL-101-C0201

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .